slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 40,741-40,770
Pages 3,683
Rows per page 30
Component
40,741-40,770 of 110,471
17
Slide compares two generations of therapy; includes clinical metrics like cORR and mDOR.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction2 hits
21
Data cut-off Sep 30, 2023. N=16 patients.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction2 hits
33
The slide uses a two-row layout to contrast GEN1 and GEN2 therapies, each with a 'Next Step' callout.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction2 hits
52
Includes study design timeline, histology details, and comparative tumor volume charts (group averages vs individual mice).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 2 hits
60
The slide uses a visual metaphor of cell-to-cell interaction to illustrate the therapeutic mechanism.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 2 hits
73
Data cut-off Sep 30, 2023. N=21 patients.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 2 hits
05
The slide uses a causal-chain framework to link platform capabilities to strategic outcomes.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle2 hits
10
The slide uses authority-citation to validate the mechanism of ITAM modification and degradation.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
26
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle2 hits
28
Includes a comparison table of clinical outcomes (ORR/CR/sCR) between NXC-201 and competitors.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle2 hits
05
The slide uses a causal-chain framework to link platform capabilities to strategic outcomes.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest2 hits
09
The slide uses academic citations to validate the mechanism of action for their CAR-T design.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Logic Chain2 hits
25
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · Cost Of Inaction2 hits
27
Includes a comparison table of clinical outcomes (ORR/CR) between NXC-201 and competitors.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action2 hits
33
The slide uses a comparative structure to present data for two distinct indications side-by-side.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action2 hits
59
The slide uses a combination of expert testimonials and a comparative table of clinical trials to validate the outpatient administration model.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action2 hits
05
The slide uses a cause-and-effect structure to map platform capabilities to strategic outcomes.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution2 hits
10
The slide uses authority-citation to validate the mechanism of ITAM modification and degradation.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 2 hits
26
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market Sizing2 hits
28
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market Sizing2 hits
34
The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 2 hits
06
The slide uses a side-by-side comparison structure to detail two distinct product programs.Innoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations 2 hits
11
The slide uses a historical context of automotive trends to frame the current shift toward autonomy.Innoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations Loop · Cost Of Inaction2 hits
12
The slide uses a combination of a bar chart for Eyewear revenue growth and a timeline for Beauté development.Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations Beat · Solution2 hits
18
The slide uses a donut chart to show the split between Retail (78%) and Wholesale (22%) channels, with YoY growth percentages for each segment.Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations Beat · FinancialsLoop · Zoom In2 hits
16
The slide uses a donut chart to show the 78/22 split between retail and wholesale, with sub-metrics for each.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Evidence & Proof2 hits
31
Includes visual references to internal policy documents and SA8000 certification.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction2 hits
32
Includes a visual representation of the 6x scale commitment relative to land use impact.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction2 hits
46
The slide uses a table to compare H1 2023 vs H1 2022, followed by bulleted commentary on margin dilution and CAPEX increases.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 2 hits
48
The chart uses a waterfall bridge to decompose revenue growth by channel (Retail, Wholesale, Royalties).Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 2 hits